HCV and Autoimmunity

Authors: Ferri, S.; Muratori, L.; Lenzi, M.; Granito, A.; Bianchi, F. B.; Vergani, D.

Source: Current Pharmaceutical Design, Volume 14, Number 17, June 2008 , pp. 1678-1685(8)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Hepatitis C virus (HCV) infection is characterized by a number of autoreactive manifestations, such as autoantibody production, cryoglobulinemia and thyroid disorders. We will analyse critically the mechanisms invoked, and partially documented, to explain such manifestations arising in genetically predisposed individuals exposed to HCV. In particular we will examine the available evidence implicating the virus in lowering the B cell activation threshold, in directly infecting lymphocytes and in inducing self-reactivity through a mechanism of molecular mimicry. We will then move to the HCV related clinical immunopathological manifestations, with a specific attention to the effects of antiviral treatment.

Keywords: Hepatitis C virus; immune system dysregulation; molecular mimicry; antiviral therapy

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161208784746824

Affiliations: 1: Institute of Liver Studies,King's College Hospital, Denmark Hill, London SE59RS, UK.

Publication date: 2008-06-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.